ClinicalTrials.gg
Active, not recruitingNCT05500599Updated Nov 29, 2024

Effects on Recovery of Children of Intravenous Formulation of Fentanyl Citrate and Midazolam Orally for Premedication

An interventional study of Fentanyl Citrate in Separation Anxiety, sponsored by Alexandria University. Active, not recruiting at 1 site in Egypt. Open to participants aged 2 Years to 8 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Alexandria University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 5 months after the study started (first participant enrolled Mar 2022, registered Aug 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
2 Years to 8 Years
Sex
All
01

Study summary

To study and compare the efficacy of intravenous formula of fentanyl citrate and midazolam administered orally for premedication in paediatric surgical patients. Primary objectives will be the effect of both premedicants on recovery. The secondary outcomes will be time of onset and level of sedation, acceptance of premedication, and adverse effects. Sixty paediatric patients of either sex, in the age group of 2-8 years, with the American Society of Anaesthesiologists (ASA) Physical status I, posted for elective Genito-urological surgeries under general anaesthesia (GA) will be studied after clearance from the Institutional Ethics Committee and after obtaining written informed consent from a parent or a legal guardian

Read the detailed description

Effects on Recovery of Children Undergoing Elective Surgery: Comparison of Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication

Introduction Paediatric preoperative anxiety has been a concerning matter for the past decades with a high prevalence and several adverse outcomes branching into social, developmental, behavioural, and perioperative fields. The anticipation of pain, separation from family, and fear of surgery are few of the factors that trigger perioperative anxiety in children. However, the routine use of anxiolytic premedication before anaesthetic induction is debated. Furthermore, premedication may significantly affect recovery from anaesthesia.

Premedication causes sedation and reduction of anxiety during separation from parents. It also provides a calm and cooperative child for smooth induction of anaesthesia. The oral route of administration of the drugs is the most acceptable and a nontraumatic route, especially in children. The total volume of the oral premedication can be kept at 0.2 ml/kg which is far below the gastric fluid volume of 0.4 ml/kg above which the risk of aspiration increases. Lipid-soluble drugs that can be supplied as water-soluble salts provide the opportunity to use it through oral route of administration for premedication.

The salt fentanyl citrate is soluble in water. These properties suggest that fentanyl citrate can be incorporated for use as a premedicant. This lipid-soluble opioid when placed in normal conditions of the mouth is 80% nonionized, making it the only opioid suitable for transmucosal absorption. However, bioavailability depends on the fraction of the dose that is absorbed through the oral mucosa (\~25%) and the fraction that is swallowed (\~75%, swallowed dose is only partially bioavailable).

Midazolam, a benzodiazepine, has been routinely used orally for premedication in children scheduled for surgery. Bioavailability of oral midazolam varies from 15% to 27% in children. It has a rapid onset and short duration of action. It is reliable in achieving sedation and anxiolysis. However, search for a better alternative continues due to concerns such as bitter taste, cognitive impairment, long-term behavioural disturbances, paradoxical reactions, hiccups, and respiratory depression.

Aim: To study and compare the efficacy of intravenous formula of fentanyl citrate and midazolam administered orally for premedication in paediatric surgical patients.

Objectives: The primary objectives will be the effect of both premedicants on recovery. The secondary outcomes will be time of onset and level of sedation, acceptance of premedication, and adverse effects.

Settings and Design: This prospective, randomized, double blind study will be conducted in Alexandria Main University hospital.

Materials and Methods Sixty paediatric patients of either sex, in the age group of 2-8 years, with the American Society of Anaesthesiologists (ASA) Physical status I, posted for elective Genito-urological surgeries under general anaesthesia (GA) will be studied after clearance from the Institutional Ethics Committee and after obtaining written informed consent from a parent or a legal guardian.

Patients with known allergy to fentanyl or midazolam, intellectual and developmental disabilities, psychosomatic disorders, history of any sedative or analgesic intake, ASA physical status ≥ 2, those with upper respiratory tract infection, history of previous surgery, and being accompanied by a non-family member will not be included in the study.

All children will be randomized to one of two groups of thirty patients each according to a computer-generated random numbers program in a double-blinded fashion, to receive either 0.5 mg/kg midazolam (Group M) or 10 μg/kg fentanyl (Group F) approximately 30 min before the induction of anaesthesia. All observers, as well as the children and their parents, will be blind to the study drug administered.

Children will be fasted 4-6 h before surgery. Before administration of the premedication, the children will be taken to the preoperative anaesthetic assessment area along with their family members. An intravenous preparation of a drug (midazolam 5 mg/ml solution, or fentanyl 50 µg/ml solution) will be mixed with apple juice a to total volume not exceeding 0.3 ml/kg body weight and given orally.

The children will be separated from their family members and taken to the operating room (OR) 30 min after the administration of premedication. In the OR, electrocardiograph, non-invasive blood pressure, and pulse oximetry monitors will be attached. Inhalation induction will be performed using sevoflurane in 100 % oxygen. An intravenous line will be secured, and fentanyl 1 µg/kg will be given intravenously for analgesia, and muscle relaxation will be provided with intravenous atracurium 0.5 mg/kg. Endotracheal tube of an appropriate size will be inserted 3 min after the administration of the muscle relaxant and capnography will be connected. Regional analgesia will be applied according to type of surgery. Measures to prevent hypothermia will be performed (e.g., warming blanket, warming intravenous fluids, etc.). Anaesthesia will be maintained with sevoflurane (2-3%), oxygen and air, and supplemental doses of atracurium 0.25 mg/kg. At the end of surgery intravenous paracetamol suppository in the dose of 15 mg/kg will be used for postoperative analgesia. Inhalational agent will be switched off, and effect of muscle relaxant will be reversed with neostigmine (0.05 mg/kg) and atropine (0.01 mg/kg) given intravenously. The patient will be extubated following return of regular, rhythmic respiration when reasonably awake. Patients will be shifted to the postoperative recovery room for observation and will be given oxygen inhalation by venturi mask. Parents will be allowed to join children.

Measurements:

  1. Children's anxiety will be assessed using the modified Yale Preoperative Anxiety Scale-Short Version at the preoperative holding area before receiving medication (Time 1), and in the operating room after separation from the parent (Time 2), where the children will not be accompanied by their family.

    The total score of the scale will be calculated as suggested by the authors that revised the scale. For each domain the patient's partial score will be divided by the maximum score obtainable in that domain (6 for the vocalizations domain and 4 for the remaining). The produced values for each domain are all added up and multiplied by 25. A score ranging from 22.92 to 100 will be obtained with higher values, representing higher states of anxiety. Thus, for study purposes, children with scores more than 30 will be considered as having anxiety and children with scores from 22,92 to 30 will be considered as not having experienced significant anxiety.

  2. Acceptance of premedication will be assessed on a three-point scale; 1 = Accepts it/likes the taste, 2 = Accepts it/but dislikes the taste. 3 = Spits/vomits the premedication. Score of 1 or 2 will be judged as satisfactory acceptance of oral premedication.
  3. Degree and onset of sedation will be assessed 15 and 30 minutes after administration of premedication by Ramsay sedation scale. Scale scored from 1 (least sedated) to 6 (most sedated).
  4. Behaviour of the child on separation from parents will be rated according to a four-point scale, i.e., the parental separation anxiety scale (PSAS): A PSAS score of 1 and 2 will be considered as acceptable separation from parents. A PSAS score of 3 and 4 will be considered as non-acceptable separation from parents
  5. Mask acceptance will be recorded using a four-point scale. The score of 1 and 2 will be considered as satisfactory mask acceptance. The score of 3 and 4 will be considered as satisfactory mask acceptance.
  6. Assessment of recovery:

    i. Emergence time (minutes): from discontinuation of anaesthesia to opening eyes spontaneously will be recorded.

    ii. Recovery time (minutes): from discontinuation of anaesthesia to a score of 8 on the modified Aldrete score will be recorded.

    iii. The quality of recovery will be evaluated using the three objective components in the modified pain/discomfort scale, each variable scoring 0-2 points (best to worst). If the total score on the pain/discomfort scale at any evaluation point exceeded 3, the child will be regarded as suffering from postanaesthetic excitement.

  1. Adverse effects: children will be observed for adverse effects if any before they left the preoperative area, and again after the surgery before they left the recovery area. Adverse effects such as hypotension, bradycardia, bradypnea or apnoea, fall in saturation, shivering, vomiting, nausea, pruritus, headache and hiccups if any will be noted for 2 hours postoperatively.
02

Conditions studied

  • Separation Anxiety

Keywords

  • recovery
  • Anxiety
  • Fentanyl
  • midazolam
  • Premedication
03

In context

Anxiety, Separation

59 studies on the registry are indexed under Anxiety, Separation; 5 are open to participants now.

This study's planned enrollment of 60 is below the median of 68 across 53 interventional studies indexed under Anxiety, Separation.

Browse Anxiety, Separation studies →

Lead sponsor

Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) Physical status I,
  • posted for elective Genito-urological surgeries under general anaesthesia (GA)

Exclusion criteria

Exclusion Criteria:

  • known allergy to fentanyl or midazolam,
  • intellectual and developmental disabilities,
  • psychosomatic disorders,
  • history of any sedative or analgesic intake,
  • ≥ 2,
  • upper respiratory tract infection,
  • history of previous surgery,
  • being accompanied by a non-family member
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    midazolam (Group M)

    receive 0.5 mg/kg midazolam orally approximately 30 min before the induction of anaesthesia

  • Active comparator
    fentanyl (Group F)

    receive 10 μg/kg fentanyl orally approximately 30 min before the induction of anaesthesia

    Drug: Fentanyl Citrate

Interventions

  • Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication

    Also known as: Midazolam

06

What researchers measure

Primary outcomes

  1. effect of both premedicants on recovery

    1. The quality of recovery will be evaluated using the three objective components in the modified pain/discomfort scale. Each variable scoring 0-2 points (best to worst). If the total score on the pain/discomfort scale at any evaluation point exceeded 3, the child will be regarded as suffering from postanaesthetic excitement. score 0 1 2 Crying Not crying Responding to pain Not responding to comforting Moving None Restless Thrashing Agitation Asleep/calm Mild agitation Sever agitation/Hysterical

    Time frame: immediately after the surgery average 2 hours postoperative

Secondary outcomes

  1. time of onset and level of sedation,

    1. Children's anxiety will be assessed using the modified Yale Preoperative Anxiety Scale-Short Version at the preoperative holding area before receiving medication (Time 1), and in the operating room after separation from the parent (Time 2). For each domain the patient's partial score will be divided by the maximum score obtainable in that domain (6 for the vocalizations domain and 4 for the remaining). The produced values for each domain are all added up and multiplied by 25. A score ranging from 22.92 to 100 will be obtained with higher values, representing higher states of anxiety. Thus, children with scores more than 30 will be considered as having anxiety and children with scores from 22,92 to 30 will be considered as not having experienced significant anxiety. 2. Degree and onset of sedation will be assessed 15 and 30 minutes after administration of premedication by Ramsay sedation scale. Scale scored from 1 (least sedated) to 6 (most sedated).

    Time frame: Before the surgery starts

  2. acceptance of premedication

    on a three-point scale. The score of 1 and 2 will be considered as satisfactory mask acceptance. The score of 3 and 4 will be considered as satisfactory mask acceptance. 1. = Excellent (unafraid, cooperative, and accepts mask easily). 2. = Good (slight fear of mask, easily reassured). 3. = Fair (moderate fear of mask, not calmed with reassurance). 4. = Poor (terrified, crying, or combative).

    Time frame: after ingestion of the premedication and before the surgery starts

  3. Time to recovery

    1. Emergence time (minutes): from discontinuation of anaesthesia to opening eyes spontaneously 2. Recovery time (minutes): from discontinuation of anaesthesia to a score of 8 on the modified Aldrete score

    Time frame: immediately after the surgery average 2 hours postoperative

07

Study locations

1 site
  • Ahmed S. Shehab
    Alexandria, 21431, Egypt
08

References and documents

Publications

  • Bergendahl H, Lonnqvist PA, Eksborg S. Clonidine in paediatric anaesthesia: review of the literature and comparison with benzodiazepines for premedication. Acta Anaesthesiol Scand. 2006 Feb;50(2):135-43. doi: 10.1111/j.1399-6576.2006.00940.x. PubMed 16430532 ↗

Related links

Individual participant data

Plan to share: Yes — there is a plan to make individual participant data (IPD) collected in this study, including data dictionaries, available to other researchers

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After study ends upon request

Access criteria: Accessible through the web site

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05500599
Responsible party
Ahmed Shehab, MD (lecturer Of Anaesthesia and Surgical intensive care, Alexandria University) — Principal investigator
First posted
Aug 15, 2022
Start date
Mar 1, 2022
Primary completion
May 31, 2025 (estimated)
Completion
Aug 28, 2025 (estimated)
Last update
Nov 29, 2024

Study contacts

Ahmed S. Shehab
principal investigator · Alexandria University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl

Start the discussion